Tags

Type your tag names separated by a space and hit enter

[The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)].
Wien Klin Wochenschr. 1979 May 11; 91(10):332-7.WK

Abstract

An open cross-over study of 20 patients with Parkinson's disease performed with two drugs containing L-dopa and a peripheral aromatic amino acid decarboxylase inhibitor (benserazide, carbidopa) confirmed the conclusions reached in other clinical trials that this combined treatment of Parkinson's disease is the most effective form of drug therapy available at present. With both drugs, Madopar or Sinemet, an optimum therapeutic result was obtained with relatively small doses of L-dopa (the reduction in L-dopa dosage amounting to about 80%). A loss of efficacy with both drugs, which has observed during long-term treatment of patients with Parkinson's disease, could be avoided by switching the patients from Sinemet to Madopar and vice versa. Determination of L-dopa in the plasma demonstrated that with either drug similar plasma levels of L-dopa were achieved during clinically effective treatment.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Controlled Clinical Trial
English Abstract
Journal Article

Language

ger

PubMed ID

452602

Citation

Podiwinsky, F, et al. "[The Combined Treatment of Parkinson's Disease With L-dopa Plus Decarboxylase Inhibitors (carbidopa, Benserazide) (author's Transl)]." Wiener Klinische Wochenschrift, vol. 91, no. 10, 1979, pp. 332-7.
Podiwinsky F, Mentasti M, Riederer P, et al. [The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)]. Wien Klin Wochenschr. 1979;91(10):332-7.
Podiwinsky, F., Mentasti, M., Riederer, P., & Birkmayer, W. (1979). [The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)]. Wiener Klinische Wochenschrift, 91(10), 332-7.
Podiwinsky F, et al. [The Combined Treatment of Parkinson's Disease With L-dopa Plus Decarboxylase Inhibitors (carbidopa, Benserazide) (author's Transl)]. Wien Klin Wochenschr. 1979 May 11;91(10):332-7. PubMed PMID: 452602.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)]. AU - Podiwinsky,F, AU - Mentasti,M, AU - Riederer,P, AU - Birkmayer,W, PY - 1979/5/11/pubmed PY - 1979/5/11/medline PY - 1979/5/11/entrez SP - 332 EP - 7 JF - Wiener klinische Wochenschrift JO - Wien Klin Wochenschr VL - 91 IS - 10 N2 - An open cross-over study of 20 patients with Parkinson's disease performed with two drugs containing L-dopa and a peripheral aromatic amino acid decarboxylase inhibitor (benserazide, carbidopa) confirmed the conclusions reached in other clinical trials that this combined treatment of Parkinson's disease is the most effective form of drug therapy available at present. With both drugs, Madopar or Sinemet, an optimum therapeutic result was obtained with relatively small doses of L-dopa (the reduction in L-dopa dosage amounting to about 80%). A loss of efficacy with both drugs, which has observed during long-term treatment of patients with Parkinson's disease, could be avoided by switching the patients from Sinemet to Madopar and vice versa. Determination of L-dopa in the plasma demonstrated that with either drug similar plasma levels of L-dopa were achieved during clinically effective treatment. SN - 0043-5325 UR - https://www.unboundmedicine.com/medline/citation/452602/[The_combined_treatment_of_Parkinson's_disease_with_L_dopa_plus_decarboxylase_inhibitors__carbidopa_benserazide___author's_transl_]_ L2 - https://medlineplus.gov/parkinsonsdisease.html DB - PRIME DP - Unbound Medicine ER -